Business
TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":" DENVER--(BUSINESS WIRE)--\nTriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced it will present a variety of new data from its innovative clinical development pipeline at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1-5, 2023, in San Diego, California.\n\n\nPresentation details for SITC 2023 are as follows:\n\n\nLate Breaker Oral Presentation: Clinical Activity of SD-101 with Immune Checkpoint Inhibition (ICI) in Metastatic Uveal Melanoma Liver Metastasis (MUM-LM) from the PERIO-01 Phase 1 Trial\nPresenter: Sapan P. Patel, M.D., Director of the Uveal Melanoma Program, The University of Texas MD Anderson Cancer Center\nAbstract: 1534\nSession: Late-Breaking Abstract Session\nTime: Saturday, November 4, 11:25 a.m. PDT\nPoster Presentation also available in the Poster Hall and in the Virtual ePoster Hall\n\n\nPoster Presentation: PERIO-03: Pressure Enabled Intrapancreatic Delivery of SD-101 with Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma – Initial Safety and Feasibility Experience\nAbstract: 647\nPresenter: Michael S. Lee, M.D., Associate Professor, The University of Texas MD Anderson Cancer Center\nTime: Friday, November 3, 9:00 a.m. – 7:00 p.m. PDT\n\n\nPoster Presentation: Checkpoint Inhibitor Administered Either Systemically of Subcutaneously Enhances the Anti-Tumor Immunity of SD-101 Delivered by Pressure-enabled Drug Delivery (PEDD) Device in Treating Liver Metastasis (LM)\nAbstract: 1123\nPresenter: Chandra C. Ghosh, Ph.D., TriSalus Life Sciences\nTime: Friday, November 3, 9:00 a.m. – 7:00 p.m. PDT\n\n\nThe presentations will be available here following their respective sessions.\n\n\nAbout TriSalus Life Sciences\n\n\nTriSalus Life Sciences® is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors.\n\n\nThe Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System ...